Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Second Line Treatment of Gastric Cancer”

109 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 109 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07337447
What this trial is testing

Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

Who this might be right for
Carcinoma, Neuroendocrine
Hospices Civils de Lyon 122
Testing effectiveness (Phase 2)Looking for participantsNCT07309185
What this trial is testing

Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy

Who this might be right for
Stomach Neoplasms
Shandong Tumor Hospital 66
Testing effectiveness (Phase 2)Ended earlyNCT04294784
What this trial is testing

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Who this might be right for
Gastric CancerGastroEsophageal Cancer
Huazhong University of Science and Technology 58
Testing effectiveness (Phase 2)Study completedNCT02501603
What this trial is testing

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Yonsei University 72
Testing effectiveness (Phase 2)Active Not RecruitingNCT05585580
What this trial is testing

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University 59
Testing effectiveness (Phase 2)Study completedNCT00729482
What this trial is testing

RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment

Who this might be right for
Stomach Neoplasm
Asan Medical Center 54
Not applicableNot Yet RecruitingNCT07139587
What this trial is testing

The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Qingxia Li 30
Testing effectiveness (Phase 2)UnknownNCT03400592
What this trial is testing

Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma

Who this might be right for
Stomach Neoplasms
Peking University 55
Testing effectiveness (Phase 2)UnknownNCT04077255
What this trial is testing

EGFR-targeted Therapy for Gastric Cancer

Who this might be right for
Adenocarcinoma of the Stomach
National Cancer Center, Korea 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07819019
What this trial is testing

A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer

Who this might be right for
Stomach NeoplasmsGastric Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center 20
Testing effectiveness (Phase 2)UnknownNCT02007148
What this trial is testing

MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
International Group of Endovascular Oncology 51
Not applicableUnknownNCT04713059
What this trial is testing

Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)

Who this might be right for
Gastric or Gastro-oesophageal Junction CarcinomaAdvanced, Relapsed Gastric or Gastro-oesophageal Junction CarcinomaSecond-line Therapy
The Affiliated Hospital of Qingdao University 62
Not applicableLooking for participantsNCT06102772
What this trial is testing

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)UnknownNCT03137004
What this trial is testing

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Who this might be right for
Advanced Gastric Cancer
Fujian Cancer Hospital 47
Testing effectiveness (Phase 2)Ended earlyNCT01994213
What this trial is testing

Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 53
Testing effectiveness (Phase 2)Ended earlyNCT03722108
What this trial is testing

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Who this might be right for
Adenocarcinoma of the StomachAdenocarcinoma of the Gastroesophageal Junction
UNICANCER 89
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06349967
What this trial is testing

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
West China Hospital 59
Testing effectiveness (Phase 2)Study completedNCT02447406
What this trial is testing

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Who this might be right for
Advanced Gastric Adenocarcinoma
Samsung Medical Center 7
Testing effectiveness (Phase 2)UnknownNCT04572542
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Who this might be right for
Locally Advanced or Metastatic Gastric Adenocarcinoma
The First Affiliated Hospital of Xiamen University 46
Testing effectiveness (Phase 2)Looking for participantsNCT07770113
What this trial is testing

A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer

Who this might be right for
GC/GEJC
The First Affiliated Hospital of Zhengzhou University 50
Next Page